A recent layoff round affecting 400 U.S. staffers was just the latest in Sumitomo Pharma’s waves of workforce reductions. Now, the Japanese pharma is reportedly weighing layoffs in its home country as revenues slide.
MARLBOROUGH, Mass., June 14, 2024 /PRNewswire/ -- Sumitomo Pharma America, Inc. (SMPA) today announced the oral presentation of data from the ongoing Phase 1/2 first-in-human study of DSP-5336 in patients with relapsed or refractory acute leukemia at the European Hematology Association (EHA) 2024 Hybrid Congress. DSP-5336 is an investigational small molecule inhibitor of the menin and mixed-lineage leukemia (MLL) protein interaction, which plays key roles in biological pathways, including cell growth regulation, cell cycle control, genomic stability, bone development, and hematopoiesis.1,2,
Sumitomo Pharma and Japan’s National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) announced last week that they will begin Phase 1 clinical trials for a universal influenza vaccine under development.
MARLBOROUGH, Mass., May 13, 2024 /PRNewswire/ -- Sumitomo Pharma America, Inc. (SMPA), announced today the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for vibegron (GEMTESA®), a beta-3 adrenergic receptor (?3) agonist, dosed once-daily (75 mg), for the treatment of men with overactive bladder (OAB) symptoms receiving pharmacological therapy for benign prostatic hyperplasia (BPH). If approved, vibegron will be the first and only beta-3 agonist for the treatment of men with OAB symptoms receiving pharmacological therapy for BPH. The FDA has set a target action date in Q3 of FY2024, under the Prescription Drug User Fee Act (PDUFA).
MARLBOROUGH, Mass., May 7, 2024 /PRNewswire/ -- Sumitomo Pharma America, Inc., (SMPA) today announced the presentation of data from URO-901-3005, a Phase 3 randomized, double-blind, parallel-group, fixed-dose study evaluating the efficacy, safety, and tolerability of vibegron (GEMTESA®) versus placebo over 24 weeks in men living with overactive bladder (OAB) and receiving pharmacological therapy for benign prostatic hyperplasia (BPH) at the American Urological Association (AUA) Annual Meeting. Following the podium presentation at AUA, these results were published in Journal of Urology.
BASEL, Switzerland - Roivant Sciences Ltd. (NASDAQ:ROIV), a biopharmaceutical company, has announced the authorization of a share repurchase program of up to $1.5 billion. This includes the acquisition of all shares held by Sumitomo Pharma, totaling $648 million, which is expected to reduce the company's shares outstanding by approximately 9% as of February 9, 2024.
Sumitomo Pharma Announces Availability of ORGOVYX® (relugolix) in Canada
CAMBRIDGE, Mass., Dec. 11, 2023 /PRNewswire/ -- Sumitomo Pharma America, Inc. (SMPA) today announced new data from the ongoing Phase 1/2 first-in-human study of DSP-5336, in patients with relapsed or refractory acute leukemia, presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition. DSP-5336 is an investigational small molecule inhibitor of the menin and mixed-lineage leukemia (MLL) protein interaction, which plays key roles in biological pathways, including cell growth regulation, cell cycle control, genomic stability, bone development, and hematopoiesis.1,2,3
Sumitomo Pharma wants overactive bladder (OAB) patients to go, go, go to the doctor’s office. Working with 21 Jump Street actor Holly Robinson Peete again, the Japanese drugmaker is seeking to reframe the urgency to go to the bathroom as a trigger for taking steps to access treatment for OAB.
CAMBRIDGE, Mass., Nov. 21, 2023 /PRNewswire/ -- Sumitomo Pharma America, Inc. (SMPA), today announced the expansion of its partnership with actress and overactive bladder (OAB) patient Holly Robinson Peete to reach people living with overactive bladder (OAB) through the Time To Go™ campaign. Time To Go is a platform designed to highlight the impact of OAB symptoms and provide education on disease management, including information on treatment options, such as GEMTESA® (vibegron), a FDA-approved prescription medication for the treatment of OAB in adults with symptoms of urge urinary incontinence, urgency, and frequency.